Sagimet Biosciences Inc.

SGMTBiotech

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Oct 30, 2026

Recruiting

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Design Trial to Evaluate the Safety and Efficacy of Denifanstat in Participants With Moderate to Severe Acne Vulgaris

Oct 22, 2026

Recruiting

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TVB-3567 in Healthy Participants With or Without Acne and to Assess the Effect of Food in Healthy Participants

Earlier

Sep 30, 2025TrialA Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

Mar 1, 2025TrialA Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis

Mar 1, 2025TrialA Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

May 1, 2023TrialA Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Nov 21, 2022TrialOpen-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects

Aug 12, 2021TrialStudy of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

1 more events

Mar 22, 2019TrialStudy of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Details